glp 1 based drugs Patients' Use GLP-1 for Weight Loss, Benefit Gains 1 medications or looking to feel their best every day. MCT2D | The Benefits of

Emerging studies are exploring the potential of GLP-1-based therapies in diverse populations and comorbidities, such as patients with type 2 diabetes or cardiovascular diseases

Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications

Indeed, our correlation analysis which suggests that greater weight loss is associated with greater pelvis BMD loss do align with prior work (Zibellini et al., 2015) and support future research to evaluate the effect of GLP1Ra use on skeletal health outcomes, particularly with GLP1Ra-based therapies capable of producing greater weight loss in older adults

10.1016/s0092-8674(02)00754-7 82 HermanD

This promotes the market growth